Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Historical Holders from Q1 2018 to Q3 2025

Symbol
RCUS on NYSE
CUSIP
03969F109
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
106M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
101M
Holdings value
$1.37B
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
184
Number of buys
90
Number of sells
-86
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GILEAD SCIENCES, INC. 25.6% -13.7% $427M 31.4M 0% GILEAD SCIENCES, INC. Nov 3, 2025
BlackRock, Inc. 9.4% $74.8M 9.98M BlackRock, Inc. Mar 31, 2025
Point72 Asset Management, L.P. 4.1% -28% $58.9M -$20.4M 4.33M -25.7% Point72 Asset Management, L.P. Sep 30, 2025

Institutional Holders of Arcus Biosciences, Inc. - Common Stock, par value $0.0001 per share (RCUS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 101M $1.37B +$17.2M $13.60 184
2025 Q2 99.8M $812M +$23M $8.14 182
2025 Q1 97.2M $763M +$76.9M $7.85 183
2024 Q4 83.9M $1.25B -$20.1M $14.89 185
2024 Q3 53.2M $814M +$20.4M $15.29 184
2024 Q2 52M $791M -$14.4M $15.23 192
2024 Q1 52.7M $996M -$4.09M $18.88 170
2023 Q4 38.6K $738K +$138K $19.10 2
2023 Q3 52.7M $947M -$31.1M $17.95 183
2023 Q2 54.6M $1.11B -$12.8M $20.31 176
2023 Q1 55.5M $1.01B +$18M $18.24 176
2022 Q4 53.8M $1.11B +$35.4M $20.68 196
2022 Q3 52M $1.36B -$628K $26.16 167
2022 Q2 52.4M $1.33B +$7.69M $25.34 158
2022 Q1 49.8M $1.57B -$27.8M $31.56 142
2021 Q4 50.8M $2.06B +$106M $40.47 134
2021 Q3 48.3M $1.68B +$59.9M $34.87 128
2021 Q2 45.1M $1.24B +$11.6M $27.46 127
2021 Q1 44.7M $1.25B +$5.08M $28.08 144
2020 Q4 44.1M $1.15B +$12.2M $25.96 140
2020 Q3 43.8M $751M +$13.2M $17.14 125
2020 Q2 41.8M $1.03B +$375M $24.74 137
2020 Q1 27M $375M +$109K $13.88 89
2019 Q4 27.1M $274M -$3.03M $10.10 74
2019 Q3 25.8M $235M -$570K $9.10 71
2019 Q2 26.4M $210M +$6.13M $7.95 74
2019 Q1 25.8M $322M -$12.8M $12.49 61
2018 Q4 26.9M $289M -$5.15M $10.77 62
2018 Q3 22.4M $313M +$920K $13.94 54
2018 Q2 22.4M $274M +$32.1M $12.24 60
2018 Q1 16.3M $251M +$251M $15.44 55